Innovent Biologics (IVBXF) AI Stock Analysis

57 Followers

Innovent Biologics

(Other OTC:IVBXF)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Revenue GrowthThe sharp increase in 2025 revenue indicates stronger commercial execution and broader product sales across Innovent’s biologics portfolio. If maintained, higher scale can support continued investment in clinical development, manufacturing capabilities, and commercialization over the next several quarters.

Negative Factors

Modest Net ProfitabilityThe relatively modest net margin shows that strong product-level profitability has not yet translated into equally strong bottom-line returns. This limits the amount of revenue growth that becomes earnings and leaves operating expenses and development spending important determinants of future profitability.

Innovent Biologics (IVBXF) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $19.33B
Dividend Yield: ―
Average Volume (3M): 2,384
Price to Earnings (P/E): 101.7
Beta (1Y): -0.30
Revenue Growth: 42.21%
EPS Growth: 9.23%
Country: US
Employees: 8,754
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Innovent Biologics Business Overview & Revenue Model

Company Description

Innovent Biologics, Inc., established in 2011 and headquartered in Suzhou, People's Republic of China, functions as a leading biopharmaceutical enterprise. The company is dedicated to the comprehensive lifecycle of antibody drug candidates, encompass...

Innovent Biologics Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

IVBXF against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HK:1530	85Outperform	HKD 36.66B	3.70	30.16%	1.73%	101.73%	249.15%
HK:9995	66Neutral	HKD 53.71B	8.22	105.60%	―	292.84%	―
HK:2696	65Neutral	HKD 26.24B	25.72	20.41%	―	32.63%	8.74%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HK:9926	48Neutral	HKD 77.46B	-67.25	-10.86%	―	42.47%	-15.80%
HK:1877	41Neutral	HKD 30.69B	-71.16	-7.23%	―	35.82%	54.40%

* Healthcare Sector Average

Performance Comparison

IVBXF and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IVBXF	Innovent Biologics	11.08	-0.80	-6.70%
HK:1530	3SBio, Inc.	14.44	-18.18	-55.73%
HK:9926	Akeso, Inc.	82.30	-33.90	-29.17%
HK:9995	RemeGen Co. Ltd. Class H	66.70	-17.95	-21.20%
HK:1877	Shanghai Junshi Biosciences Co., Ltd. Class H	14.95	-9.79	-39.57%
HK:2696	Shanghai Henlius Biotech, Inc. Class H	48.12	-17.13	-26.25%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Innovent Biologics AI Stock Analysis